IGF1R and pachyonychia congenita: The efficacy of another IGF-1R inhibitor, ganitumab, was evaluated in a phase II clinical trial and found to improve the overall survival of metastatic PC patients over a period of 6 months while ensuring manageable toxicity levels (42).